Trial NCT03207867

View at ClinicalTrials.gov 
Org. Study IDs: CNIR178X2201
Secondary IDs: 2017-000241-49

Last trial update was posted on 2024-03-01

MeSH Interventions

Spartalizumab

MeSH Conditions

Carcinoma, Renal Cell Lymphoma Lymphoma, Non-Hodgkin Triple Negative Breast Neoplasms

Other Conditions

DLBCL, Diffused Large B Cell Lymphoma Head and Neck Cancer MSS, Microsatellite Stable Colon Cancer Melanoma NSCLC, Non Small Cell Lung Cancer Pancreatic Cancer RCC, Renal Cell Cancer TNBC, Triple Negative Breast Cancer Urothelial Cancer mCRPC, Metastatic Castration Resistant Prostate Cancer

Stopping Reasons

Sponsor decision

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID